OTX-TP, a glaucoma treatment candidate from Ocular Therapeutix, failed to meet its phase 3 primary endpoint of statistically significant superiority in mean IOP reduction, according to a press release.
An intracanalicular insert that delivers a preservative-free travoprost formulation, OTX-TP is designed to lower IOP for up to 90 days in patients with primary open-angle glaucoma or ocular hypertension.
The double-masked, placebo-controlled phase 3 trial included 554 subjects who were treated with either OTX-TP or placebo insert. IOP reduction was measured at nine different time points: 8 a.m.,
Uncategorized